Novartis to open ‘new chapter’ of CVD treatment with NHS collaboration

Novartis aims to work alongside NHS England to tackle the burden of cardiovascular disease (CVD) in the UK.

Announcing its intentions, Novartis said the current proposal is to create a pioneering collaboration that brings together three projects that aim to tackle the healthcare challenge of CVD, whilst also providing increased opportunities for UK life science sector development.

The current Memorandums of Understanding (MOUs), which form the basis of the collaboration, were negotiated and signed by The Medicines Company prior to its acquisition by Novartis.

The first proposal, upon regulatory approval and the National Institute for Health and Care Excellence (NICE) assessment, would be to provide inclisiran to secondary prevention ASCVD patients through a population-level agreement.

Inclisiran is currently in Phase III development for secondary prevention patients with expected European Medicines Agency (EMA) regulatory filing in Q1 2020.

Providing inclisiran to this high-risk population could make a significant contribution towards meeting the NHS long-term commitment to preventing 150,000 cardiovascular deaths over 10 years.

The second proposal is to explore a large-scale clinical trial to evaluate the use of inclisiran to patients at very high risk of having their first cardiac event (primary prevention).

The final proposal includes the creation of an industry and academic consortium to look at manufacturing synergies that could improve the efficiency and scale at which the UK can manufacture oligonucleotide medicines – such as inclisiran.

Novartis has a unique opportunity with inclisiran to open up a new chapter in the treatment of cardiovascular disease, the world’s leading cause of mortality and disability,” said Vas Narasimhan, CEO of Novartis.

“We’re confident that innovative approaches like this will enable us to accelerate access timelines, deliver on our broader commitment to generating leading scientific evidence, and ensure continuous improvement in manufacturing efficiency and optimisation.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Related news

Takeda opens R&D cell therapy manufacturing facility

Takeda is expanding its cell therapy manufacturing capabilities with the opening of a new 24,000 sq ft cell therapy manufacturing facility at its R&D...

Valneva forges COVID-19 vaccine partnership with UK Gov

Valneva, a French vaccine company focused on prevention against diseases with major unmet needs, has forged a major vaccine partnership with the UK government...

Gilead Sciences to acquire Immunomedics for $21bn

Gilead Sciences is bolstering its oncology offering acquiring Immunomedics in a deal that values the latter at $21 billion. The agreement will provide Gilead with...

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...